Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Investor5876on Jun 27, 2024 3:57pm
68 Views
Post# 36109562

RE:It Was Just A Typo

RE:It Was Just A TypoI'm not surprised to have confirmation about the P.O.A error.

Brad Thompson left the stage a long time ago. 

A silly mistake, but also another data point added to the list of evidence suggesting ONC is very poorly managed. 

Yes, it is very strange that ONC has no plans to submit a correction to SEDI. 

This is a legal document and Brad Thompson has been given power of attorney over a particular matter invovling options. 

And ONC apparently views this as a trivial matter. 

It would take them five minutes to submit a correction. 

Either the management of ONC is asleep at the wheel and utterly useless, or they don't care becuase it will be a moot point in the near term. Unfortunately, I believe it is the former. 


<< Previous
Bullboard Posts
Next >>